Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIK NASDAQ:ATRS NASDAQ:LMAT NASDAQ:SIBN NASDAQ:SRDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIKAnika Therapeutics$11.27-4.3%$11.57$10.47▼$29.12$161.62M0.6476,158 shs76,049 shsATRSAntares Pharma$5.59$5.59$3.11▼$5.60$955.06M1.153.29 million shs6 shsLMATLeMaitre Vascular$83.68-2.4%$82.72$71.42▼$109.58$1.89B0.82170,219 shs84,551 shsSIBNSiBone$17.20-8.4%$18.23$11.70▼$20.05$732.98M0.93393,206 shs382,421 shsSRDXSurmodics$30.87-0.5%$29.03$26.00▼$42.25$441.41M1.31221,371 shs75,417 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIKAnika Therapeutics0.00%+0.04%0.00%-17.38%-56.98%ATRSAntares Pharma0.00%0.00%0.00%0.00%0.00%LMATLeMaitre Vascular0.00%-0.87%+2.84%+1.04%+0.30%SIBNSiBone0.00%-6.83%-5.81%+28.65%+26.94%SRDXSurmodics0.00%+2.95%+6.16%+8.35%-26.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIKAnika Therapeutics4.321 of 5 stars3.83.00.03.72.71.70.6ATRSAntares Pharma1.8843 of 5 stars0.00.00.03.60.60.83.1LMATLeMaitre Vascular2.2803 of 5 stars2.21.03.30.01.62.51.3SIBNSiBone4.0012 of 5 stars3.52.00.03.32.02.50.6SRDXSurmodics4.3609 of 5 stars3.34.00.03.41.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIKAnika Therapeutics 3.50Strong Buy$20.0077.46% UpsideATRSAntares Pharma 0.00N/AN/AN/ALMATLeMaitre Vascular 2.33Hold$97.8316.91% UpsideSIBNSiBone 3.00Buy$22.5030.81% UpsideSRDXSurmodics 2.50Moderate Buy$43.0039.29% UpsideCurrent Analyst Ratings BreakdownLatest ATRS, ANIK, LMAT, SRDX, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ANIKAnika TherapeuticsBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$20.00 ➝ $19.005/6/2025SIBNSiBoneTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $22.005/6/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/6/2025SIBNSiBoneNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/30/2025SRDXSurmodicsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/17/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/16/2025ANIKAnika TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIKAnika Therapeutics$119.91M1.35$0.10 per share118.15$10.51 per share1.07ATRSAntares Pharma$183.98M5.19$0.13 per share43.89$1.03 per share5.43LMATLeMaitre Vascular$219.86M8.60$2.39 per share35.03$15.00 per share5.58SIBNSiBone$176.60M4.15N/AN/A$3.98 per share4.32SRDXSurmodics$126.08M3.50$0.31 per share99.78$8.33 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIKAnika Therapeutics-$56.38M-$3.88N/AN/AN/A-41.28%-7.22%-5.64%8/6/2025 (Estimated)ATRSAntares Pharma$46.29M$0.2423.2925.41N/A21.90%7.43%4.92%N/ALMATLeMaitre Vascular$44.04M$1.9842.2638.562.2119.96%13.53%9.78%8/5/2025 (Estimated)SIBNSiBone-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)SRDXSurmodics-$11.54M-$1.39N/A38.59N/A-16.34%-7.10%-4.77%7/30/2025 (Estimated)Latest ATRS, ANIK, LMAT, SRDX, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025LMATLeMaitre Vascular$0.57N/AN/AN/A$62.48 millionN/A8/4/2025Q2 2025SIBNSiBone-$0.19N/AN/AN/A$48.12 millionN/A7/30/2025Q3 2025SRDXSurmodics-$0.21N/AN/AN/A$28.04 millionN/A5/5/2025Q1 2025SIBNSiBone-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/30/2025Q2 2025SRDXSurmodics-$0.06-$0.13-$0.07-$0.36$32.23 million$28.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIKAnika TherapeuticsN/AN/AN/AN/AN/AATRSAntares PharmaN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.96%N/A40.40%14 YearsSIBNSiBoneN/AN/AN/AN/AN/ASRDXSurmodicsN/AN/AN/AN/AN/ALatest ATRS, ANIK, LMAT, SRDX, and SIBN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIKAnika TherapeuticsN/A5.734.53ATRSAntares Pharma0.103.082.87LMATLeMaitre Vascular0.4816.4913.83SIBNSiBone0.218.537.26SRDXSurmodics0.275.143.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIKAnika Therapeutics91.53%ATRSAntares Pharma50.41%LMATLeMaitre Vascular84.64%SIBNSiBone98.11%SRDXSurmodics96.63%Insider OwnershipCompanyInsider OwnershipANIKAnika Therapeutics9.64%ATRSAntares Pharma5.90%LMATLeMaitre Vascular9.50%SIBNSiBone4.00%SRDXSurmodics8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIKAnika Therapeutics30014.34 million12.96 millionOptionableATRSAntares Pharma201170.85 million160.77 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableSIBNSiBone35042.62 million40.91 millionOptionableSRDXSurmodics45014.30 million13.03 millionOptionableATRS, ANIK, LMAT, SRDX, and SIBN HeadlinesRecent News About These CompaniesSurmodics, Inc. (SRDX) stock price, news, quote & history - Yahoo FinanceJuly 3, 2025 | au.finance.yahoo.comFY2025 EPS Estimates for Surmodics Reduced by Zacks ResearchJuly 3, 2025 | marketbeat.comQ1 Earnings Estimate for Surmodics Issued By Zacks ResearchJuly 3, 2025 | americanbankingnews.comZacks Research Has Bearish Outlook for Surmodics Q1 EarningsJuly 2, 2025 | marketbeat.comQuidelOrtho (QDEL) Down 18% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comWhy Is SurModics (SRDX) Up 6% Since Last Earnings Report?May 30, 2025 | zacks.comSurmodics, Ballinasloe, offers production operator opportunitiesMay 15, 2025 | advertiser.ieAAre Options Traders Betting on a Big Move in Surmodics Stock?May 2, 2025 | msn.comSRDX Stock Down Following Q2 Earnings Miss, Gross Margin ContractsMay 1, 2025 | zacks.comSurmodics stock takes another hit on Q2 miss and 2025 guidanceApril 30, 2025 | massdevice.comSurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to SayApril 30, 2025 | zacks.comSurModics (SRDX) Reports Q2 Loss, Misses Revenue EstimatesApril 30, 2025 | zacks.comSurmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial GuidanceApril 30, 2025 | businesswire.comA Look at Surmodics's Upcoming Earnings ReportApril 30, 2025 | benzinga.comSurmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30April 28, 2025 | businesswire.comResults Published From TRANSCEND Study of Surmodics SurVeil DCBApril 23, 2025 | evtoday.comESurmodics publishes TRANSCEND trial dataApril 22, 2025 | markets.businessinsider.comSurmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated BalloonApril 22, 2025 | businesswire.comIllinois joins FTC suit to block GTCR’s takeover of SurmodicsApril 17, 2025 | chicagobusiness.comCAG Ellison Joins Suit to Block Surmodics AcquisitionApril 17, 2025 | tcbmag.comTBarrington Sticks to Their Hold Rating for SurModics (SRDX)April 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATRS, ANIK, LMAT, SRDX, and SIBN Company DescriptionsAnika Therapeutics NASDAQ:ANIK$11.27 -0.51 (-4.33%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.30 +0.04 (+0.31%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Antares Pharma NASDAQ:ATRSAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.LeMaitre Vascular NASDAQ:LMAT$83.68 -2.07 (-2.41%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$83.66 -0.02 (-0.02%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.SiBone NASDAQ:SIBN$17.20 -1.58 (-8.41%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$17.20 0.00 (0.00%) As of 07/11/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Surmodics NASDAQ:SRDX$30.87 -0.15 (-0.48%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$30.86 -0.02 (-0.05%) As of 07/11/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
